scholarly journals Multicenter prospective observational study on safety and efficacy of regional citrate anticoagulation in CVVHD in the presence of liver failure: the Liver Citrate Anticoagulation Threshold Study (L-CAT)

Critical Care ◽  
2011 ◽  
Vol 15 (S1) ◽  
Author(s):  
T Slowinski ◽  
S Morgera ◽  
M Joannidis ◽  
T Henneberg ◽  
R Stocker ◽  
...  
Keyword(s):  
Observational Study ◽  
Liver Failure ◽  
Prospective Observational Study ◽  
Regional Citrate Anticoagulation ◽  
Safety And Efficacy ◽  
Citrate Anticoagulation ◽  
Multicenter Prospective Observational Study

scholarly journals Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study

Critical Care ◽  
2012 ◽  
Vol 16 (4) ◽  
pp. R162 ◽  
Author(s):  
Caroline Schultheiß ◽  
Bernd Saugel ◽  
Veit Phillip ◽  
Philipp Thies ◽  
Sebastian Noe ◽  
...  
Keyword(s):  
Observational Study ◽  
Liver Failure ◽  
Prospective Observational Study ◽  
Regional Citrate Anticoagulation ◽  
Citrate Anticoagulation ◽  
Continuous Venovenous Hemodialysis

scholarly journals Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19

2020 ◽  
Vol 7 (9) ◽  
pp. 1428-1436 ◽  
Author(s):  
Mingxing Huang ◽  
Man Li ◽  
Fei Xiao ◽  
Pengfei Pang ◽  
Jiabi Liang ◽  
...  
Keyword(s):  
Adverse Events ◽  
Observational Study ◽  
Prospective Observational Study ◽  
Viral Rna ◽  
Absolute Difference ◽  
Safety And Efficacy ◽  
Full Dose ◽  
Half Dose ◽  
Multicenter Prospective Observational Study ◽  
Historical Controls

Abstract Effective therapies are urgently needed for the SARS-CoV-2 pandemic. Chloroquine has been proved to have antiviral effect against coronavirus in vitro. In this study, we aimed to assess the efficacy and safety of chloroquine with different doses in COVID-19. In this multicenter prospective observational study, we enrolled patients older than 18 years old with confirmed SARS-CoV-2 infection excluding critical cases from 12 hospitals in Guangdong and Hubei Provinces. Eligible patients received chloroquine phosphate 500 mg, orally, once (half dose) or twice (full dose) daily. Patients treated with non-chloroquine therapy were included as historical controls. The primary endpoint is the time to undetectable viral RNA. Secondary outcomes include the proportion of patients with undetectable viral RNA by day 10 and 14, hospitalization time, duration of fever, and adverse events. A total of 197 patients completed chloroquine treatment, and 176 patients were included as historical controls. The median time to achieve an undetectable viral RNA was shorter in chloroquine than in non-chloroquine (absolute difference in medians −6.0 days; 95% CI −6.0 to −4.0). The duration of fever is shorter in chloroquine (geometric mean ratio 0.6; 95% CI 0.5 to 0.8). No serious adverse events were observed in the chloroquine group. Patients treated with half dose experienced lower rate of adverse events than with full dose. Although randomized trials are needed for further evaluation, this study provides evidence for safety and efficacy of chloroquine in COVID-19 and suggests that chloroquine can be a cost-effective therapy for combating the COVID-19 pandemic.

Safety and Efficacy of Regional Citrate Anticoagulation during Plasma Adsorption Plus Plasma Exchange Therapy for Patients with Acute-on-Chronic Liver Failure: A Pilot Study

2019 ◽  
Vol 48 (3) ◽  
pp. 223-232 ◽  
Author(s):  
Yuanji Ma ◽  
Fang Chen ◽  
Yan Xu ◽  
Ming Wang ◽  
Taoyou Zhou ◽  
...  
Keyword(s):  
Pilot Study ◽  
Liver Failure ◽  
Plasma Exchange ◽  
Chronic Liver ◽  
Regional Citrate Anticoagulation ◽  
Chronic Liver Failure ◽  
Safety And Efficacy ◽  
Citrate Anticoagulation ◽  
Citrate Accumulation ◽  
Heparin Anticoagulation

Background: Patients with acute-on-chronic liver failure (ACLF) might be at risk for citrate accumulation during plasma adsorption plus plasma exchange (PE) therapy with regional citrate anticoagulation (RCA). Objectives: To assess the safety and efficacy of RCA during double plasma molecular adsorption system (DPMAS) plus PE therapy for patients with ACLF. Method: A prospective nonrandomized controlled pilot study was conducted at West China Hospital of Sichuan University. Patients with ACLF were enrolled to heparin anticoagulation (HA) group and RCA group. Serial blood samples were taken. Patients were followed up for 3 months. Results: Twenty-four patients with 94 sessions of HA and 28 patients with 106 sessions of RCA were enrolled. RCA method did not affect the therapeutic efficacy, the function of extracorporeal circulation, and the prognosis of these patients. The occurrences of citrate accumulation in RCA group were 0.0, 67.0, 100.0, 34.0, and 0.0% before DPMAS therapy, at the end of DPMAS therapy, immediately after PE therapy, 2 h after PE therapy, and the next morning, while that in HA group were 0.0, 0.0, 100.0, 7.4, and 0.0%, respectively. The occurrences of citrate accumulation at the end of DPMAS therapy and at 2 h after PE therapy in RCA group were much higher than that in HA group (67.0 vs. 0.0%, p = 0.000; 34.0 vs. 7.4%, p = 0.000, respectively). Although the trend of citrate accumulation in RCA group was much more obvious than that in HA group during and after DPMAS plus PE therapy (p = 0.000), the values on the next morning were similar between the 2 groups (p > 0.05). The main alteration of acid–base status was metabolic alkalosis with no difference between the 2 groups. Conclusions: RCA might be safe and effective in patients with ACLF receiving plasma adsorption plus PE therapy. RCA method might offer an alternative anticoagulation method for them.

scholarly journals Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19

2020 ◽  
Author(s):  
Mingxing Huang ◽  
Man Li ◽  
Fei Xiao ◽  
Jiabi Liang ◽  
Pengfei Pang ◽  
...  
Keyword(s):  
Adverse Events ◽  
Observational Study ◽  
Prospective Observational Study ◽  
Viral Rna ◽  
Absolute Difference ◽  
Safety And Efficacy ◽  
Full Dose ◽  
Half Dose ◽  
Multicenter Prospective Observational Study ◽  
Historical Controls

AbstractBackgroundEffective therapies are urgently needed for the SARS-CoV-2 pandemic. Chloroquine has been proved to have antiviral effect against coronavirus in vitro. In this study, we aimed to assess the efficacy and safety of chloroquine with different doses in COVID-19.MethodIn this multicenter prospective observational study, we enrolled patients older than 18 years old with confirmed SARS-CoV-2 infection excluding critical cases from 12 hospitals in Guangdong and Hubei Provinces. Eligible patients received chloroquine phosphate 500mg, orally, once (half dose) or twice (full dose) daily. Patients treated with non-chloroquine therapy were included as historical controls. The primary endpoint is the time to undetectable viral RNA. Secondary outcomes include the proportion of patients with undetectable viral RNA by day 10 and 14, hospitalization time, duration of fever, and adverse events.ResultsA total of 197 patients completed chloroquine treatment, and 176 patients were included as historical controls. The median time to achieve an undetectable viral RNA was shorter in chloroquine than in non-chloroquine (absolute difference in medians −6.0 days; 95% CI −6.0 to −4.0). The duration of fever is shorter in chloroquine (geometric mean ratio 0.6; 95% CI 0.5 to 0.8). No serious adverse events were observed in the chloroquine group. Patients treated with half dose experienced lower rate of adverse events than with full dose.ConclusionsAlthough randomised trials are needed for further evaluation, this study provides evidence for safety and efficacy of chloroquine in COVID-19 and suggests that chloroquine can be a cost-effective therapy for combating 102 the COVID-19 pandemic.

Endoscope‐assisted transoral accessory parotid mass excision: Multicenter prospective observational study

2019 ◽  
Vol 130 (5) ◽  
pp. 1218-1226 ◽  
Author(s):  
Jin Pyeong Kim ◽  
Dong Kun Lee ◽  
Jeong Hwan Moon ◽  
Jun Sun Ryu ◽  
Seung Hoon Woo
Keyword(s):  
Observational Study ◽  
Prospective Observational Study ◽  
Multicenter Prospective Observational Study
Sign in / Sign up

Export Citation Format

Share Document